Journal article
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer
QT Le, R Fisher, KS Oliner, RJ Young, H Cao, C Kong, E Graves, RJ Hicks, GA McArthur, L Peters, B O'Sullivan, A Giaccia, D Rischin
Clinical Cancer Research | Published : 2012
Abstract
Purpose: Hepatocyte growth factor (HGF) is a hypoxia-induced secreted protein that binds to cMet and regulates interleukin (IL)-8 expression. We evaluated the role of circulating HGF and IL-8 as prognostic and predictive factors for efficacy of tirapazamine (TPZ), a hypoxic cell cytotoxin. Experimental Design: Patients with stages III to IV head and neck cancer were randomized to receive radiotherapy with cisplatin (CIS) or CIS plus TPZ (TPZ/CIS). Eligibility for the substudy included plasma sample availability for HGF and IL-8 assay by ELISA and no major radiation deviations (N = 498). Analyses included adjustment for major prognostic factors. p16 INK4A staining (human papillomavirus surrog..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by 1 R01 CA118582 (Q.-T. Le, R. Fisher, R.J. Young, H. Cao, C. Kong, E. Graves, R.J. Hicks, G.A. McArthur, A. Giaccia, and D. Rischin), NHMRC project grant (R. Fisher, R.J. Young, G. A. McArthur, L. Peters, and D. Rischin), and P01-CA67166 (Q.-T. Le, H. Cao, and A. Giaccia).